Search Results

Shortly after Eli Lilly launched its direct-to-consumer service for its weight loss drug Zepbound, the Mayo Clinic has announced a new telehealth service that will offer direct access to GLP-1 weight-loss medications.

The pharmaceutical giant has launched a telehealth-connected website to allow patients to directly order the weight loss drug, as well as insulin products and a migraine drug, direct from the company.

The Food and Drug Administration approved 55 new treatments in 2023, representing a nearly 50% increase from the year before, with Pfizer gaining the highest number of high-profile approvals covering a wide range of illnesses.

The list, which highlights first-in-class medications and vaccines, represents "meaningful steps forward" when it comes to weight loss, Alzheimer's, birth control and postpartum depression, as selected by GoodRx pharmacists.

Specialty drug costs keep going up for plan sponsors Here are a few considerations employers and their brokers and consultants need to take into account in the coming years.   

For some employers, certain benefits of increasing coverage for obesity medication outweigh the cons of a high price tag.

"I think the FDA is struggling to get its arms around how to regulate it," said Kyle Faget, a partner at Foley & Lardner. "We're really in the nascent stage with AI."

While less than half of large employers currently cover the new generation of obesity drugs, an additional 18% say they're considering adding them amid surging interest, according to findings from Mercer.